Extended Safety and Effectiveness of Tralokinumab in Individuals with Moderate-to-Severe Atopic Dermatitis Over a 6-Year Period: Final Outcomes from the ECZTEND Open-Label Extension Study - Poll - MDSpire

Extended Safety and Effectiveness of Tralokinumab in Individuals with Moderate-to-Severe Atopic Dermatitis Over a 6-Year Period: Final Outcomes from the ECZTEND Open-Label Extension Study

  • By

  • Andrew Blauvelt

  • H. Chih-Ho Hong

  • Norito Katoh

  • Richard G. Langley

  • Vivian Laquer

  • Aleksandra Lesiak

  • Ketty Peris

  • Julien Seneschal

  • Juan-Francisco Silvestre

  • Richard B. Warren

  • Andreas Wollenberg

  • Matthew Zirwas

  • Niels Højsager Bennike

  • Farzaneh Safavimanesh

  • Ann-Marie Tindberg

  • Kristian Reich

  • February 5, 2026

  • 0 min

Share

Original Source(s)

Extended Safety and Effectiveness of Tralokinumab in Individuals with Moderate-to-Severe Atopic Dermatitis Over a 6-Year Period: Final Outcomes from the ECZTEND Open-Label Extension Study

  • by Andrew Blauvelt, H. Chih-Ho Hong, Norito Katoh, Richard G. Langley, Vivian Laquer, Aleksandra Lesiak, Ketty Peris, Julien Seneschal, Juan-Francisco Silvestre, Richard B. Warren, Andreas Wollenberg, Matthew Zirwas, Niels Højsager Bennike, Farzaneh Safavimanesh, Ann-Marie Tindberg, Kristian Reich

  • February 5, 2026

Related Content

Smartwatch May Track AD Status in Children

Wearable-derived scratching measures align with disease activity and short-term treatment response in pediatric patients with atopic dermatitis.

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness

What Causes the Itch in Dermatitis?

Scientists discover the mechanism that drives inflammation and itching in the chronic skin condition

  • February 3, 2026

  • 2 min